Redefining Value in Transthyretin Amyloidosis Cardiomyopathy Care: Innovations in Diagnosis, Treatment, and Access

Program Description

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the misfolding of transthyretin proteins into amyloid fibrils that deposit in the heart, leading to restrictive cardiomyopathy and heart failure. Despite its severity, ATTR-CM is frequently underdiagnosed or delayed as symptoms often overlap with more common conditions. This session is designed to equip managed care professionals and pharmacists with the clinical and economic insights necessary to resolve diagnostic and treatment delays in ATTR-CM. Through a review of current therapies, including established TTR stabilizers, as well as the expanding role of TTR gene silencers and other investigational agents, expert speakers will explore critical considerations in treatment sequencing, the interpretation of serum TTR as a biomarker, and the application of health economic data to inform sustainable formulary decisions. By highlighting the pivotal role of the managed care pharmacist in multidisciplinary teams, this program aims to optimize patient-centered access, improve therapy adherence, and leverage emerging diagnostic tools to reduce the systemic and economic burden of ATTR-CM.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key symptoms and common diagnostic pitfalls for transthyretin amyloidosis cardiomyopathy (ATTR-CM) and their impact on timely diagnosis and optimal resource use.
• Explain the comparative safety, efficacy, cost considerations, and mechanisms of action for available and emerging therapies for ATTR-CM.
• Apply team-based care models and health economic data to optimize managed care contributions to patient-centered access, therapy adherence, and sustainable formulary decisions for ATTR-CM.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-094-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Dejan (Dan) Landup, PharmD, HF-Cert, has the following relevant financial relationships with ineligible companies to disclose:

Regional advisory board: Alnylam, BridgeBio

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, FAMCP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Adam C Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms